Company patents
TRANSLATE BIO, INC.
TRANSLATE BIO, INC. demonstrates a strong focus on "Pharmaceutical Preparations," which constitutes 79.0% of its patent portfolio, indicating a core strategy in drug development. While there was a significant surge in "Heterocyclic Compounds (Pharma)" with a 200.0% YoY growth in 2024 and "Nanotechnology" with a 200.0% YoY growth in 2025, the sharp declines across most categories so far in 2026, such as "Therapeutic Activity (Pharma)" (-81.8%) and "Genetic & Microbiological Assays" (-100.0%), suggest a potential shift in patenting priorities or a natural fluctuation in a partial year's data.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
143 US filings (since 2023) · 10 categories · 13 themes
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development of lipid-based nanoparticles, liposomes, or other molecular platforms to encapsulate and deliver therapeutic agents, particularly nucleic acids, to target tissues or improve pharmacokinetics.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Developing advanced bioreactor designs, fermentation strategies, and downstream processing techniques to optimize yield, purity, and efficiency of biotechnological production.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Patents
Showing 1-10 of 16
Protein & Peptide Engineering